Axsome (NASDAQ: AXSM) planned 7,500-share sale disclosed

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. has a planned sale of 7,500 shares of common stock, according to a Form 144 notice. The shares are to be sold through Charles Schwab & Co., Inc. on the NASDAQ, with an aggregate market value of $1,383,327.00. The filing lists total common shares outstanding as 50,412,640.

The 7,500 shares were acquired on 01/21/2026 via an employee stock option exercise from Axsome Therapeutics, Inc., using a broker payment for a cashless exercise on the same date. The Form 144 also includes a representation that the seller does not know of any undisclosed material adverse information about the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	7500	1383327.00	50412640	01/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/21/2026	Employee Stock Option Exercise	Axsome Therapeutics, Inc.			7500	01/21/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Axsome Therapeutics (AXSM) Form 144 disclose?

The Form 144 discloses a planned sale of 7,500 shares of Axsome Therapeutics, Inc. common stock on the NASDAQ through Charles Schwab & Co., Inc..

How many AXSM shares are planned to be sold under this Form 144?

The filing indicates a planned sale of 7,500 shares of common stock with an aggregate market value of $1,383,327.00.

How were the Axsome Therapeutics shares acquired before this planned sale?

The 7,500 shares were acquired on 01/21/2026 through an employee stock option exercise from Axsome Therapeutics, Inc. using a broker payment for a cashless exercise.

What is the aggregate market value of the AXSM shares to be sold?

The aggregate market value of the 7,500 Axsome Therapeutics shares to be sold is listed as $1,383,327.00.

How many Axsome Therapeutics common shares are outstanding as referenced in the filing?

The Form 144 lists 50,412,640 shares of Axsome Therapeutics, Inc. common stock as outstanding.

On which exchange will the Axsome Therapeutics shares be sold?

The Form 144 states that the 7,500 Axsome Therapeutics shares are planned to be sold on the NASDAQ.